Use of flunarizine and method for controlling number of intercellular mitochondria
US-2024325381-A1 · Oct 3, 2024 · US
Pan-kinase activation and evaluation of signaling pathways
US9040249B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9040249-B2 |
| Application number | US-201213665776-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2012 |
| Priority date | Sep 4, 2008 |
| Publication date | May 26, 2015 |
| Grant date | May 26, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of identifying and assessing the efficacy of an inhibitor of ribosomal S6 pathway activation, said method comprising the steps of: a) contacting a population of cells comprising a protein activated by the ribosomal S6 pathway with a first inhibitor, wherein said first inhibitor is a putative inhibitor of extracellular signal-related kinase (ERK) or phosphoinositide 3-kinase (PI3K); b) contacting said population of cells with a second inhibit…
Assignees
Inventors
Classifications
Physics · mapped topic
Physics · mapped topic
- G01N33/5008Primary
Physics · mapped topic
Physics · mapped topic
- G01N33/5041Primary
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9040249B2 cover?
- Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathwa…
- Who is the assignee on this patent?
- Beckman Coulter Inc, Univ Health Network
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5008. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue May 26 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).